# Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

> **NCT04756765** · PHASE2 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Breast Cancer
- Advanced Breast Cancer

## Interventions

- **DRUG:** Talazoparib Tosylate

## Key facts

- **NCT ID:** NCT04756765
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-23
- **Primary completion:** 2024-12-18
- **Final completion:** 2024-12-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to changes in the treatment landscape, the study faced significant recruitment challenges. As no patients were enrolled, the sponsor requested study closure
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04756765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04756765, "Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04756765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*